X4 Pharmaceuticals, Inc XFOR
X4 Pharmaceuticals, Inc (Nasdaq: XFOR) is a hematology drug developer. Its lead program, Mavorixafor (4WARD trial), is in Phase 3 for chronic neutropenia (congenital, acquired primary autoimmune, idiopathic) with recurrent/serious infections. Its next catalyst on record is Mavorixafor 4WARD: Top-line data (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Mavorixafor 4WARD — Top-line data (H2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| XOLREMDI (mavorixafor) | WHIM syndrome (12 years and older) | small molecule | Approved |
| Mavorixafor - 4WARD pivotal Phase 3 | chronic neutropenia | small molecule | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
- Incyte Corp INCY
- Grifols SA GRFS
- Disc Medicine, Inc. IRON
- Agios Pharmaceuticals, Inc. AGIO
- Geron Corporation GERN
- Nuvectis Pharma, Inc. NVCT
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.